Previous Article | Next Article 
Mol Cell Biol, August 1998, p. 4872-4882, Vol. 18, No. 8
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Tissue Hyperplasia and Enhanced T-Cell Signalling
via ZAP-70 in c-Cbl-Deficient Mice
Maria A.
Murphy,1
Ralf G.
Schnall,1
Deon J.
Venter,1 2
Louise
Barnett,3
Ivan
Bertoncello,1
Christine B. F.
Thien,4
Wallace Y.
Langdon,4 and
David
D. L.
Bowtell1 *
Trescowthick Research Laboratories, Peter
MacCallum Cancer Institute, Melbourne 3000,1
Department of Pathology, University of
Melbourne,2 and
The Walter and Eliza
Hall Institute of Medical Research, The Royal Melbourne
Hospital,3, Parkville 3050, Victoria, and
Department of Pathology, University of Western Australia,
Nedlands 6907, Western Australia,4 Australia
Received 17 February 1998/Returned for modification 16 April
1998/Accepted 5 May 1998
 |
ABSTRACT |
The c-Cbl protein is tyrosine phosphorylated and forms complexes
with a wide range of signalling partners in response to various growth
factors. How c-Cbl interacts with proteins, such as Grb2, phosphatidylinositol 3-kinase, and phosphorylated receptors, is well
understood, but its role in these complexes is unclear. Recently, the
Caenorhabditis elegans Cbl homolog, Sli-1, was shown to act as a negative regulator of epidermal growth factor receptor signalling. This finding forced a reassessment of the role of Cbl proteins and
highlighted the desirability of testing genetically whether c-Cbl acts
as a negative regulator of mammalian signalling. Here we investigate
the role of c-Cbl in development and homeostasis in mice by targeted
disruption of the c-Cbl locus. c-Cbl-deficient mice were
viable, fertile, and outwardly normal in appearance. Bone development
and remodelling also appeared normal in c-Cbl mutants, despite a
previously reported requirement for c-Cbl in osteoclast function.
However, consistent with a high level of expression of c-Cbl in the
hemopoietic compartment, c-Cbl-deficient mice displayed marked changes
in their hemopoietic profiles, including altered T-cell receptor
expression, lymphoid hyperplasia, and primary splenic extramedullary
hemopoiesis. The mammary fat pads of mutant female mice also showed
increased ductal density and branching compared to those of their
wild-type littermates, indicating an unanticipated role for c-Cbl in
regulating mammary growth. Collectively, the hyperplastic histological
changes seen in c-Cbl mutant mice are indicative of a normal role for
c-Cbl in negatively regulating signalling events that control cell
growth. Consistent with this view, we observed greatly increased
intracellular protein tyrosine phosphorylation in thymocytes following
CD3
cross-linking. In particular, phosphorylation of ZAP-70 kinase
in thymocytes was uncoupled from a requirement for CD4-mediated Lck
activation. This study provides the first biochemical characterization
of any organism that is deficient in a member of this unique protein family. Our findings demonstrate critical roles for c-Cbl in
hemopoiesis and in controlling cellular proliferation and signalling by
the Syk/ZAP-70 family of protein kinases.
 |
INTRODUCTION |
The c-Cbl protooncogene
is the cellular homolog of the acutely transforming v-Cbl
oncogene, which was originally identified in the murine Cas NS-1
retrovirus (27). v-Cbl induces pre-B-cell and
myeloid tumors in mice, transforms rodent fibroblast cell lines, and
encodes a protein of 357 amino acids which encompasses the
amino-terminal region of c-Cbl (2). Recently the
913-amino-acid product of c-Cbl has been identified as a
ubiquitous substrate of protein tyrosine kinases that is rapidly
phosphorylated following stimulation of growth factor, antigen, and
integrin receptors (4, 11, 13, 17, 25, 33, 36-38, 40, 52,
60). c-Cbl protein has no known catalytic function but contains a
novel phosphotyrosine binding (PTB) domain, a RING finger domain, an extensive proline-rich region, and a carboxy-terminal leucine zipper.
To date four Cbl proteins have been described: c-Cbl and Cbl-b in
mammals, Drosophila Cbl, and Caenorhabditis
elegans Cbl (known as Sli-1) (2, 19, 21, 34, 64). The
partial sequence of a third human Cbl homolog has recently been lodged
in the National Institutes of Health expressed sequence tag (EST)
database (AA112513). All Cbl proteins are highly conserved in their
amino-terminal PTB and RING finger domains but are divergent at
their carboxy termini. The carboxy-terminal half of c-Cbl contains
proline-rich SH3-binding domains, three major sites of tyrosine
phosphorylation for SH2 domain interactions, and the binding site for
interactions with 14-3-3 proteins (30).
While the multiple complexes that c-Cbl is found in suggest diverse
roles in signal transduction, a definitive function for c-Cbl has not
emerged. The most revealing clue about the function of Cbl proteins
came originally from genetic studies in C. elegans, where
Sli-1 was identified as a negative regulator of the epidermal growth
factor (EGF) receptor tyrosine kinase (Let-23) (20). These
experiments demonstrated that Sli-1 acts at the level of Let-23 and the
C. elegans Grb2 homolog (Sem5), consistent with mammalian
studies that place Cbl at an early point in tyrosine kinase-mediated
signal transduction (64). Recent studies have provided
initial evidence that mammalian c-Cbl may also negatively regulate the
activity of cytoplasmic protein tyrosine kinases. Overexpression of
c-Cbl in mast cells suppresses Syk kinase activity (39) and
reduces Ras-dependent AP1 activation following T-cell ligation in
Jurkat cells (43). In addition, treatment of cells with
antisense c-Cbl can enhance the activation of the JAK-STAT pathway (56). It is unclear whether these effects on kinase activity are direct. Interestingly, c-Cbl has been shown to be transiently ubiquitinated in colony-stimulating factor 1 (CSF-1) stimulated macrophages, leading to the suggestion that c-Cbl may negatively regulate signalling in these cells by participating in
ubiquitin-mediated degradation of the CSF-1 receptor (60).
Studies of oncogenic forms of c-Cbl have also provided clues to Cbl
function. c-Cbl can be rendered oncogenic either by a large
carboxy-terminal truncation (v-Cbl) or by a small internal deletion
immediately amino terminal to the RING finger (70Z-Cbl) (1, 2,
27). Studies of v-Cbl demonstrated that the PTB domain forms a
direct association with the EGF receptor and the ZAP-70 tyrosine kinase
(4, 17, 31, 53). These findings indicate that v-Cbl may
complete with c-Cbl for binding sites on activated receptor complexes,
thereby blocking regulation by c-Cbl and resulting in transformation.
In contrast, transformation by 70Z-Cbl appears to involve a positive
signalling mechanism. Expression of 70Z-Cbl causes hyperphosphorylation
of a range of substrates by enhancing the kinase activity of the
platelet-derived growth factor and EGF receptors (3, 54).
These studies indicate that 70Z-Cbl has lost its ability to function as
a negative regulator but still provides docking sites for complexes
that mediate growth-stimulatory signals. This notion is supported by
the finding that 70Z-Cbl, but not c-Cbl or v-Cbl, induces
transcriptional activation of the nuclear factor of activated T cells
(NFAT) (29). 70Z-Cbl-mediated NFAT activation was markedly
enhanced by stimulation with calcium ionophore and abrogated by the
expression of a dominant-negative Ras, implicating 70Z-Cbl in the Ras
signalling pathway. Reduced activation of Erk2 and decreased
stimulation of a Ras-sensitive AP1 reporter in c-Cbl-overexpressing
Jurkat cells (43) is also consistent with a role for c-Cbl
in T-cell receptor (TCR)-mediated Ras activation.
These studies have led to the realization that c-Cbl may function as a
negative regulator of protein tyrosine kinases and also to provide
docking sites for a multitude of signalling proteins. To study these
proposed roles in detail, we have generated mice that are deficient in
c-Cbl. The results obtained with these animals provide compelling
evidence that mammalian c-Cbl is involved in the control of tissue
cellularity and that it functions as a negative regulator of protein
tyrosine kinases.
 |
MATERIALS AND METHODS |
c-Cbl targeting vector and isolation of targeted ES cells and
mice.
Murine c-Cbl genomic clones were isolated from a
UNI-ZAP 129Sv library (Stratagene) by hybridization with a
32P-labelled murine c-Cbl cDNA, and the
positions of the coding exons were determined by standard procedures
(44). A 7-kb XbaI fragment was subcloned into the
XbaI site of pBSII (Stratagene), and from this an
EcoRI-HindIII fragment that contained a c-Cbl coding exon, beginning at amino acid codon 146, was subcloned into
pALTER (Promega). A ClaI site was introduced at amino acid codon 153 by site-directed mutagenesis, converting the sequence CAAATTATCCCTGATCTT to
CAAATTATCGAGGATCTT. This fragment was returned to the 7-kb XbaI fragment, and a 1.8-kb pGKNeo-selectable
marker was inserted between the ClaI and
HindIII sites, removing amino acid codons 153 to 190 and
creating an in-frame stop codon within the pGK promoter. The construct
was linearized with XhoI and electroporated into W9.5
embryonic stem (ES) cells (26). Targeted ES cells were
selected in G418 at 200 µg/ml. DNA was obtained for Southern analysis
of these clones by using proteinase K and sodium dodecyl sulfate (SDS)
and was restricted with BamHI. To identify targeted clones,
filters were probed with a 32P-labelled genomic fragment
outside the targeting construct (Fig. 1A). As predicted, targeted clones gave a
new band of 4.2 kb. Fifteen clones were obtained at a frequency of 1 clone per 27 Neor ES cell clones.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 1.
Targeted disruption of the c-Cbl locus. (A)
Mutation strategy in which c-Cbl coding sequences were replaced by a
neomycin resistance cassette (pGKneo). Predicted sizes are shown for
the wild-type and mutant alleles following BamHI digestion
of genomic DNA and probing with the indicated fragment outside the
targeting construct. B, BamHI; H, HindIII; X,
XbaI; R, EcoRI. (B) Southern blot analysis of
tail DNA from progeny of an intercross of heterozygous mice, restricted
with BamHI and probed with the fragment indicated in A. Mice
bearing the mutant allele showed the predicted restriction fragment.
|
|
Four G418-resistant clones that had only single integration events, as
evidenced by probing a Southern blot with neomycin-specific probe, were
used to generate chimeric mice by microinjection of embryonic day 3.5 C57BL/6J blastocysts. Male chimeras were mated to C57BL/6J females, and
germ line transmission of the ES cell genome was detected by coat
color. Southern blot analysis of the tail DNA of pups was performed by
standard procedures (44), and approximately half of the
agouti pups were heterozygous for the c-Cbl mutation. C57BL/6J and
129Sv mice were obtained from the Animal Resource Center, Murdoch,
Western Australia. Western blot analysis of tissues from homozygous
mutant mice was performed essentially as described previously
(59) but with an antiserum directed to a C-terminal c-Cbl
peptide, C15 (Santa Cruz).
Thymocyte stimulation by antibody cross-linking.
Single-cell
suspensions of thymocytes were prepared at 5 × 107/ml
in RPMI 1640 supplemented with 5% fetal calf serum (FCS) (RPMI-5% FCS). Hamster anti-CD3
(500A2) or biotinylated anti-CD3
(500A2) and anti-CD4 (L3T4) antibodies were added to the cells at 10 µg/ml, and the cells were incubated on ice for 10 min and washed once in
RPMI-5% FCS. Cross-linking was carried out by addition of 12.5 µg
of anti-hamster immunoglobulin G (IgG) antibodies/ml in RPMI-5% FCS
or 40 µg of streptavidin/ml in RPMI. The cells were incubated on ice
for 10 min before stimulation at 37°C for 5 min or various times as
indicated. All antibodies were obtained from PharMingen.
Immunoprecipitations and immunoblotting.
Following
stimulation, the thymocytes were washed once in ice-cold
phosphate-buffered saline and then lysed at 3 × 107
to 5 × 107 cells/ml in ice-cold Nonidet P-40 (NP-40)
lysis buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 2 mM EDTA, 1 mM
sodium orthovanadate, 1% NP-40) supplemented with 10 µg of
aprotinin/ml, 10 mM NaF, and 1 µg (each) of chymostatin, leupeptin,
and pepstatin/ml. After being incubated for 10 min on ice, the lysates
were cleared by centrifugation at 14,000 × g for 8 min. The cleared lysates (0.5-ml aliquots) were then analyzed by
immunoprecipitation and immunoblotting as previously described
(4). Anti-Lck antibodies were purchased from Zymed,
anti-SLP-76 and anti-Fyn antibodies were purchased from Santa Cruz,
anti-ZAP-70 antibodies were purchased from Transduction Laboratories
and L. Samelson, and anti-phosphotyrosine (4G10) antibodies were
purchased from B. Druker.
Immune complex kinase assays.
Anti-Lck immunoprecipitates
from unstimulated or anti-CD3- and anti-CD3-CD4-stimulated thymocytes
were washed three times in NP-40 lysis buffer and then washed once in
kinase buffer (20 mM MOPS [morpholinepropanesulfonic acid] buffer
[pH 7.0], 5 mM MgCl2, 5 mM MnCl2).
Immunoprecipitates were then incubated with 25 µl of kinase buffer
containing 12.5 µCi of [
-32P]ATP (4,000 Ci/mmol;
Bresatec) for 10 min at room temperature with occasional mixing. The
kinase reaction was stopped by addition of 1 ml of ice-cold modified
RIPA buffer (20 mM MOPS [pH 7.0], 150 mM NaCl, 1 mM EDTA, 1% NP-40,
1% sodium deoxycholate, 0.1% SDS), the mixture was centrifuged
briefly, and the supernatant containing unincorporated radioisotope was
discarded. Immunoprecipitates were washed a further three times in RIPA
buffer, by which time minimal radioactivity was detected in the
discarded supernatant. Samples were resuspended in 30 µl of 1×
Laemmli sample buffer, incubated at room temperature for 10 min, and
then boiled for 3 min, and the supernatant was transferred to a fresh
tube. The samples were separated by electrophoresis through a SDS-10%
polyacrylamide gel, dried at 80°C under vacuum for 30 min, and
analyzed by autoradiography after a 30-min exposure.
Thymocyte proliferation assay.
Thymocytes (4 × 105) from normal or c-Cbl-deficient mice were cultured in
200 µl of RPMI-10% FCS with plate-bound anti-TCR
(H57-597)
antibodies for up to 3 days in round-bottom 96-well culture dishes
(Nunc). Eight hours before being harvested, the cells were pulsed with
0.6 µCi of [3H]thymidine and the radioactivity of
individual filters was measured by liquid scintillation counting. All
cultures were in triplicate, and the results are presented as mean
counts per minute ± standard error of the mean from thymuses of
10 wild-type and 10 c-Cbl
/
mice.
Assay of myeloid progenitors.
Bone marrow and spleen cell
suspensions (2,500 and 10,000 cells per dish, respectively) were
assayed for the presence of macrophage lineage progenitor cells in a
double-layer nutrient agar culture system exactly as previously
described (5). A predetermined optimal concentration of
partially purified pregnant mouse uterus extract was used as a source
of macrophage CSF (6). Colonies of at least 50 cells were
scored after 14 days of incubation. The values are means ± standard errors of the mean for mice 7 to 9 weeks of age except where
indicated. The statistical significance was determined by the Student
t test, using the SigmaStat statistical package (version
2.0; Jandel Corp., St. Rafael, Calif.).
Histological preparations.
Standard histology was performed
as described previously (59). Tartrate-resistant acid
phosphatase stains for osteoclasts were performed with reagents from
Sigma, according to the manufacturer's protocols. Whole-mount stains
of mammary fat pads were performed as described previously
(58).
Flow cytometric analysis.
Immunophenotyping was performed
with a FACStarPlus flow cytometer. List files of at least 10,000 events
were collected for each cell population and were analyzed with Lysis II
software. CD4 and CD8 cell subsets and B220-positive cells expressing
IgM or IgD were analyzed by two-color fluorescence (fluorescein
isothiocyanate or phycoerythrin) following fluorescence compensation.
Monoclonal antibodies directed against murine CD3
(145-2C11), CD4
(GK1.5), CD8 (53-6.7), TCR
(H57), IgM (R6-60.2), and IgD were
purchased from PharMingen. The monoclonal antibody directed against
B220 (RA36B2) (9) was purified from rat hybridoma
conditioned medium. Streptavidin-phycoerythrin was purchased from
Caltag Laboratories.
 |
RESULTS |
Targeting of the c-Cbl locus.
To generate
c-Cbl-deficient mice, we first sought to disrupt one allele of the gene
in ES cells by homologous recombination of a targeting construct into
the c-Cbl locus (Fig. 1A). Following electroporation of the
targeting construct, multiple ES cell clones were obtained in which the
c-Cbl gene was precisely disrupted. Four such clones were
used to generate mice with a germ line mutation. Homozygous
c-Cbl
/
mice, detected by Southern blot
analysis (Fig. 1B), were produced in expected numbers from an
intercross of heterozygotes (Table 1).
c-Cbl is widely expressed in adult mouse tissues but is most abundant
in the testes and thymus (28). Despite this, homozygous c-Cbl
/
male and female animals were fertile,
and the litter sizes of c-Cbl
/
intercrosses
were comparable to those of wild-type controls (Table 2). Homozygous mutant animals had normal
growth rates and longevity (data not shown) and were externally
indistinguishable from their wild-type littermates.
To further confirm that the gene had been functionally disrupted,
Western blot analysis was performed on tissue lysates with an antiserum
directed to the C terminus of c-Cbl which does not cross-react with the
related Cbl-b protein. There was a complete absence of full-length
protein in all tissues tested in homozygous mutant mice. Trace amounts
of a smaller protein were apparent, however, in the thymus, where c-Cbl
is especially abundant and easy to detect (Fig.
2A). A survey of other tissues, including those of the spleen, lymph node, breast, and brain, also showed very
weak expression of the smaller protein in proportion to the normal
levels of the protein in wild-type tissue (data not shown). The
residual protein was seen only in c-Cbl+/
and
c-Cbl
/
mice and therefore appeared to be a
product of the mutant allele rather than a normal splice variant.
Consistent with this notion, the transcript corresponding to this
protein was cloned only from mutant mice when reverse transcription and
PCR amplification were performed. DNA sequence analysis demonstrated
that the smaller protein was encoded by an in-frame splicing event that
deleted the targeted exon (Fig. 2B). The predicted protein lacked
highly conserved residues in the region of the PTB domain of c-Cbl
(Fig. 2B) (31, 53). Thus, the c-Cbl mice lack any wild-type
c-Cbl protein and produce trace amounts of an abnormal protein that lacks highly conserved residues within the PTB domain, indicating that
these mice are likely to be null for c-Cbl function.

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 2.
Western blot analysis of c-Cbl mutant mice. (A) Protein
levels of c-Cbl were greatly reduced in homozygote mutant thymocytes
(open arrowhead), although a trace amount of a slightly smaller protein
remained (solid arrowhead). Note that the smaller protein is only
apparent in homozygous and heterozygous mutant mice. (B) Alignment
showing the positions of splice donor (SD) and splice acceptor (SA)
sites adjacent to the targeting site (c-Cbl /
stop) and the sequences deleted in the smaller protein (panel A, solid
arrowhead). The majority of the c-Cbl protein was truncated by
insertion of a Neor cassette several residues downstream of
a site corresponding to a null allele in Sli-1
(syl143 stop). Cloning of the mRNA for the residual mutant
protein demonstrated that it was produced by an atypical, in-frame
splicing event that was generated only from the mutant allele. Black
boxes, identical amino acids; grey boxes, conservative amino acid
differences; white boxes, nonconservative amino acid differences.
|
|
Hemopoietic and mammary hyperplasia.
We performed a
histological survey of neonatal and adult mice to identify tissue
abnormalities in c-Cbl-deficient mice. A prominent feature of
c-Cbl
/
mice was a severe splenic disorder
characterized by splenomegaly (Table 3
and Fig. 3), fibrosis, and extensive
extramedullary hemopoiesis (EMH), in which large numbers of
megakaryocytes and normoblasts were apparent in the spleen parenchyma.
Increased EMH in the spleens and livers of mutants was apparent from
birth (data not shown). EMH can occur as a secondary response to
failure of bone marrow hemopoiesis or due to anemia, for example,
following hemorrhage. However, erythrocyte numbers and other blood
parameters examined were comparable in mutant and wild-type animals,
except for an increase in circulating platelets in
c-Cbl
/
mice (Table 3). The thrombocytosis
seen in c-Cbl
/
mice may reflect the large
numbers of splenic megakaryocytes seen in these animals (Fig. 3D). Bone
marrow cellularity and the incidence of bone marrow progenitor
colony-forming cells (CFC) were not significantly different in
wild-type and c-Cbl
/
mice (Table 3). There
was an increase in the number of CFC in some
c-Cbl
/
mice, but due to a large variability
between animals, the changes noted were not significantly different
from those of the controls. Lymph nodes were significantly enlarged in
c-Cbl
/
mice and were comprised of increased
numbers of both T and B cells (Table 3 and data not shown).
Interestingly, mice aged between 5 and 5.5 weeks had significantly
increased numbers of thymocytes, but by 7 to 9 weeks of age, thymic
cellularity in c-Cbl
/
mice was comparable to
that in their wild-type littermates (Table 3).

View larger version (123K):
[in this window]
[in a new window]
|
FIG. 3.
Primary splenomegaly, EMH, and mammary duct hyperplasia
in c-Cbl / mice. (A to D) Hematoxylin and
eosin staining of splenic sections from wild-type (A and C) and
c-Cbl / (B and D) mice. (A and B) Low-power
magnification demonstrating splenomegaly and disruption of the
architecture of the spleen of a c-Cbl /
mutant. (C and D) High-power magnification of the boxed regions in
panels A and B showing EMH with large numbers of megakaryocytes
(arrowheads) in the spleen of a c-Cbl /
mutant (D) compared with that of its normal littermate (C). (E to H)
Whole-mount stains of the abdominal mammary fat pads of virgin
13-week-old female mice. Excessive ductal branching was seen in
c-Cbl / mice (G and H) compared to that in
age-matched wild-type mice (E and F).
|
|
We observed that the mammary fat pads of virgin adult female mice were
slightly thickened compared with those of controls. When stained as
whole-mount preparations to reveal the ductal development, a striking
increase in duct density and branching was observed in mature virgin
c-Cbl
/
mice compared with that in controls
(Fig. 3E to H). Examination of other branching and secretory tissues,
including the glands associated with the male reproductive system and
the salivary glands, did not reveal any morphological difference
between wild-type and c-Cbl
/
mice (data not
shown). c-Cbl expression was readily detectable in wild-type animals by
Western blot analysis in all tissues affected by the c-Cbl mutation
(data not shown).
The splenic, lymphoid, and mammary changes we observed appeared to
uniformly affect each type of tissue and were not suggestive of focal
clonal expansion(s). Whether these abnormalities represent low-grade
neoplastic changes is unclear; however, we have not observed the
development of progressive, malignant tumors in
c-Cbl
/
mice maintained up to 12 months of
age.
Bone development and remodelling.
c-Cbl has been reported to
be required for osteoclast activity in an in vitro bone resorption
assay (51). To investigate whether there were any skeletal
abnormalities in mutant animals, mice were examined by high-resolution
X ray and histologically to reveal general morphology and osteoclasts.
X-ray analysis showed distinct marrow cavities in the long bones of
mutant animals and demonstrated that their general skeletal
architecture was normal (Fig. 4A and B).
This was confirmed by hematoxylin and eosin staining of decalcified
femurs and tibias from juvenile and adult mice and serial sections
through neonatal mice (Fig. 4C and D and data not shown). Finally, bone
sections stained for tartrate-resistant acid phosphatase as a marker of
osteoclasts revealed normal numbers and morphology of osteoclasts in
mutant animals compared with those in their littermates (Fig. 4E and
F). A more detailed in vitro analysis of osteoclast activity and a
histomorphometric analysis of bones from mutant mice may be required to
reveal a subtle requirement for c-Cbl in bone remodelling.

View larger version (178K):
[in this window]
[in a new window]
|
FIG. 4.
Bone morphology in c-Cbl / and
wild-type control mice. (A and B) X-ray analysis of 7-week-old
wild-type (A) and c-Cbl / (B) mice showing
comparable skeletal morphology. (C and D) Hematoxylin and eosin
staining of the femoral heads of a 6-week-old wild-type mouse (C) and
its c-Cbl / littermate (B). The morphologies
of the growth plate (bar) and marrow cavity (mc) were comparable. (E
and F) Sections comparable to those in panels C and D stained for
tartrate-resistant acid phosphatase to reveal osteoclasts. The numbers
and morphologies (high-power insets of boxed regions) of osteoclasts
were comparable in wild-type (E) and c-Cbl /
(F) mice.
|
|
Abnormalities in T-cell profiles.
c-Cbl is highly expressed in
the thymus and has been implicated in TCR and B-cell receptor
signalling (11, 13, 22). To investigate its role in T- and
B-cell development, and to further characterize the hemopoietic
abnormalities in the c-Cbl
/
mouse, we
performed flow cytometric analyses on 7- to 9-week-old mice. Although
c-Cbl
/
mice had normal numbers of thymic
cells (Table 3), there was a pronounced alteration in their phenotype.
There was a large increase in the number of TCR
- and
CD3
-expressing thymocytes in the c-Cbl
/
mice compared with those in their wild-type littermates (Fig. 5). The percentage of CD4-CD8
double-positive and CD4 and CD8 single-positive thymic cells was
largely normal in c-Cbl
/
mice, except for a
tendency for fewer CD8 single-positive cells. The slight reduction in
CD8 single-positive cells was not statistically significant when data
from a large number of animals was compared and may therefore reflect a
chance occurrence or a phenotype that occurs at low penetrance in the
c-Cbl
/
mice (data not shown). Although
CD4/CD8 ratios were largely unaffected in
c-Cbl
/
mice, there was a consistent increase
in the intensity of CD4 and CD8 staining in the double-positive
thymocytes, but not in single-positive cells (Fig. 5). Similar changes
in the TCR
-CD
and CD4-CD8 profiles were observed in the spleens
of c-Cbl
/
mice, but they were less
pronounced and a proportion of animals appeared largely normal (data
not shown).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 5.
Altered T-cell parameters in
c-Cbl / mice. Flow cytometry profiles from
wild-type (WT) and c-Cbl / cells as
indicated. The flow cytometry profiles were consistent in 12 or more
mice of each genotype.
|
|
Whereas the thymic-T-cell changes seen in
c-Cbl
/
mice were highly reproducible, more
variable changes were observed in B cells. The mesenteric lymph nodes
of c-Cbl
/
mice demonstrated absolute
increases in both B and T cells (Table 3). The distribution of immature
and mature B cells in the spleen, lymph nodes, and bone marrow,
assessed by IgM, IgD, and B220 staining, was generally normal (data not
shown). However, some c-Cbl
/
mice had a
larger proportion of IgM-positive, IgD-negative cells in the bone
marrow and spleen. Antibody stains for cells in the granulocyte and
macrophage/monocyte lineages did not reveal any abnormalities in
mutant hemopoietic tissues (data not shown). Depletion of c-Cbl
therefore had its most apparent impact on cells in the lymphoid
lineage, most notably in the T-cell compartment.
Given the changes observed by flow cytometric analysis, we investigated
the functional integrity of the immune system by measuring antibody
responses to antigenic challenge. Mice were immunized with the hapten
nitrophenol coupled either to lipopolysaccharide or keyhole limpet
hemocyanin, in order to measure T-cell-independent and T-cell-dependent
antigens, respectively. The immunized mice were then assayed for their
isotypic responses over a 3-week period. The magnitude and timing of
the responses to these antigens were comparable in mutant and wild-type
animals (data not shown). In vitro proliferation of thymocytes and
peripheral T cells in response to TCR cross-linking was also
investigated. While there was a trend towards a higher proliferative
response in c-Cbl
/
thymocytes, this was not
statistically significant (Fig. 6). Further evaluation of response to limiting amounts of cross-linking antibodies or to ovalbumin with T cells from antigen-primed animals failed to detect significant proliferative differences between wild-type and c-Cbl
/
cells (data not shown).

View larger version (73K):
[in this window]
[in a new window]
|
FIG. 6.
Analysis of thymocyte proliferation in response to
anti-TCR stimulation. Thymocytes from wild-type and
c-Cbl / mice were cultured with plate-bound
anti-TCR (H57-597) antibodies for the indicated times and pulsed
with 0.6 mCi of [3H]thymidine 8 h before being
harvested. All cultures were in triplicate, and the results represent
mean radioactive values ± standard errors of the mean from cells
harvested from the thymuses of 10 wild-type and 10 c-Cbl / mice. No response was observed in the
absence of antibody stimulation.
|
|
CD3-mediated activation of ZAP-70 in c-Cbl-deficient
thymocytes.
c-Cbl is a prominent target of the TCR-regulated Fyn
kinase (55). Overexpression of c-Cbl reduces
Fc
Receptor I-mediated phosphorylation of the Syk tyrosine kinase in
mast cells (39) and decreases TCR-mediated, Ras-dependent
activation of AP1 (43). To investigate the intracellular
consequences of loss of c-Cbl, we examined signalling events in
thymocytes before and after TCR activation by cross-linking with
anti-CD3 antibodies. Immunoblotting of lysates with
anti-phosphotyrosine antibodies revealed that unstimulated
c-Cbl
/
thymocytes had higher basal levels of
tyrosine-phosphorylated proteins in the 50- to 60-kDa molecular mass
range compared with normal cells (Fig.
7A). Anti-CD3 cross-linking of thymocytes
from normal mice resulted in a large induction of c-Cbl tyrosine
phosphorylation, consistent with Fyn kinase activation, and an increase
in the tyrosine phosphorylation of proteins in the 50- to 60-kDa
molecular mass range. In contrast, stimulation of
c-Cbl
/
thymocytes through the TCR-CD3
complex revealed the tyrosine phosphorylation of additional substrates
not evident in normal cells. Most striking was the massive induction in
tyrosine phosphorylation of three polypeptides with molecular masses of
70, 75, and 80 kDa and the hyperphosphorylation of a protein of a
mobility equivalent to that of pp36-38 (48) (Fig. 7A).

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 7.
(A) Anti-CD3 stimulation of thymocytes from
c-Cbl-deficient mice induces the tyrosine phosphorylation of proteins
that are not detectably phosphorylated in normal thymocytes. Thymocytes
from c-Cbl+/+, c-Cbl+/ ,
and c-Cbl / mice were left unstimulated or
stimulated with anti-CD3 ( CD3) antibodies for 5 min at 37°C before
lysis and immunoblotting with anti-phosphotyrosine (Anti-P-Tyr)
antibodies. The 76-kDa phosphoprotein from the stimulated
c-Cbl / thymocytes has a mobility equivalent
to that of SLP-76. (B) Anti-CD3-induced phosphorylation of ZAP-70 in
c-Cbl-deficient thymocytes is not dependent on Lck activation.
Thymocytes from c-Cbl+/+ or
c-Cbl / mice were left unstimulated (unstim)
or stimulated with anti-CD3 or anti-CD3-CD4 antibodies for 5 min at
37°C. Cell lysates were either analyzed by immunoblotting with
anti-phosphotyrosine antibodies or immunoprecipitated (i.p.) with
anti-Lck or anti-ZAP-70 antibodies. The anti-Lck immunoprecipitates
were analyzed in an immune complex kinase assay for Lck kinase
activity, and the anti-ZAP-70 immunoprecipitates were analyzed by
anti-phosphotyrosine immunoblotting.
|
|
The electrophoretic mobility of these proteins raised the possibility
that anti-CD3 stimulation of Cbl-deficient thymocytes had
inappropriately phosphorylated and activated the ZAP-70 protein tyrosine kinase, which is known to phosphorylate the substrates SLP-76
and pp36-38 (44a, 62). ZAP-70 in normal thymocytes is activated via the CD4-coupled tyrosine kinase Lck (63). We
compared the effects of anti-CD3 and anti-CD3-CD4 stimulation of
thymocytes from normal and c-Cbl-deficient mice (Fig. 7B). Again
anti-CD3 stimulation of normal thymocytes resulted in the
phosphorylation of a limited number of substrates, with c-Cbl being
most prominent, whereas in c-Cbl-deficient thymocytes tyrosine
phosphorylation of the 70- to 80-kDa substrates predominated.
Immunoprecipitation of ZAP-70 and immunoblotting with
anti-phosphotyrosine antibodies confirmed the lack of activated ZAP-70
in anti-CD3-stimulated normal thymocytes, whereas in c-Cbl-deficient
thymocytes ZAP-70 is inappropriately activated (Fig. 7B). Following
costimulation of normal thymocytes with anti-CD3-CD4, there was an
induction of a hyperphosphorylated 70-kDa protein and, to a lesser
extent, proteins of approximately 75 and 80 kDa. Anti-ZAP-70
immunoprecipitation of costimulated normal thymocytes confirmed the
identity of this protein as tyrosine-phosphorylated ZAP-70. The
immunoprecipitation also showed that ZAP-70 tyrosine phosphorylation
was slightly enhanced in the c-Cbl-deficient thymocytes, but there was
a disproportionately large increase in the phosphorylation of the 75-, 80, and 36- to 38-kDa proteins compared to that in normal thymocytes
(Fig. 7B).
These findings suggested that c-Cbl was functioning as a negative
regulator of ZAP-70. To test whether this regulation is a direct effect
or is mediated indirectly by c-Cbl's effect on Lck, we analyzed Lck in
an immune complex kinase assay. Lck is an upstream activator of ZAP-70
that phosphorylates tyrosine 493 in the kinase domain of ZAP-70,
resulting in catalytic activation of ZAP-70 (8, 61). The
results of the immune complex kinase assay shown in Fig. 7B
demonstrated a lack of activated Lck in both normal and c-Cbl-deficient
thymocytes stimulated by anti-CD3 antibodies, consistent with the
requirement for CD4 cross-linking for Lck activation (63).
Thus, it appears that the inappropriate activation of ZAP-70 via CD3 in
the c-Cbl-deficient thymocytes was occurring without the overt
activation of Lck. In contrast costimulation by anti-CD3-CD4 antibodies
results in a large induction of Lck kinase activity in both normal and
c-Cbl-deficient thymocytes. Lck induction and ZAP-70 phosphorylation
were slightly higher in the c-Cbl-deficient thymocytes, but there was a
disproportionately increased association of Lck and ZAP-70.
Furthermore, there is a very large increase in the level of
phosphorylation of the 75- to 80-kDa proteins in
c-Cbl
/
cells relative to that in wild-type
control cells, which was disproportionate to the level of ZAP-70
phosphorylation. Taken together these findings suggest that the
depletion of c-Cbl greatly enhances ZAP-70 activity via a mechanism
that independent of its immediate upstream activator.
To test the possibility that this enhanced phosphorylation could be a
consequence of decreased tyrosine phosphatase activity rather than a
deregulation of ZAP-70 activity, we compared a time course of tyrosine
phosphorylation of proteins in anti-CD3
-stimulated thymocytes.
Dephosphorylation of prominent substrates occurred at a comparable rate
in both wild-type and c-Cbl
/
thymocytes
(Fig. 8A), indicating that increased
kinase activity is responsible for the increased level of
phosphoproteins seen in c-Cbl
/
thymocytes.
Furthermore, there appears to be some degree of specificity, as the
enhancement in tyrosine phosphorylation due to c-Cbl depletion appears
to be restricted to about four substrates, which is in contrast to the
array of hyperphosphorylated proteins in pervanadate-treated thymocytes
(data not shown).

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 8.
(A) Time course analysis comparing the kinetics of
tyrosine phosphorylation and dephosphorylation of protein substrates in
c-Cbl+/+ and c-Cbl /
thymocytes following anti-CD3 stimulation. Thymocytes were stimulated
for the times indicated, lysed, and immunoblotted with
anti-phosphotyrosine antibodies. (B) Enhanced activation of MAP kinase
Erk2 in CD3-stimulated thymocytes from
c-Cbl / mice. c-Cbl+/+
and c-Cbl / thymocytes were left unstimulated
(0') or stimulated with anti-CD3 antibodies for 5 (5') or 15 (15') min.
MAP kinase activation was assessed by SDS-polyacrylamide gel
electrophoresis and immunoblotting of lysates with an antibody that
recognizes both p42 (Erk2) and p44 (Erk1) to detect electrophoretic
mobility shifts. The mobility shift representing an increase in Erk2
phosphorylation in c-Cbl / thymocytes is
indicated by an open arrowhead.
|
|
Consistent with the increased phosphorylation seen in
c-Cbl
/
thymocytes we also found an increased
level of activated Erk2 following anti-CD3 stimulation (Fig. 8B). This
finding is consistent with the suppression of Erk2 activity by c-Cbl
overexpression in Jurkat T cells (43) and the ability of
70Z-Cbl to induce NFAT activation via the Ras pathway (29).
Collectively these findings indicate that c-Cbl functions to directly
regulate the activity of ZAP-70 in stimulated thymocytes and that the
absence of c-Cbl results in enhanced phosphorylation of downstream
targets of ZAP-70. Furthermore, these findings support the model
originally proposed for Cbl regulating the events leading to Ras
activation in C. elegans (64).
 |
DISCUSSION |
Current understanding of Cbl protein function comes from the
convergence of two streams of work: biochemical studies of mammalian cells, which identify c-Cbl as a major phosphoprotein that forms diverse protein complexes, and more limited genetic studies that implicate Cbl proteins as negative regulators of signalling (39, 43, 64). The work described here unifies these experimental studies by describing the effects of germ line loss of c-Cbl in mice
and provides a coherent model for c-Cbl function.
Mutation of the c-Cbl locus.
While our disruption of the
c-Cbl gene resulted in a complete absence of wild-type
protein, the mice unexpectedly produced a very low level of a variant
protein at less than 5% of wild-type levels. This protein was the
result of an in-frame transcriptional splice around the targeted exon
and was specific to the mutant allele. Whether the residual protein
retains any biological activity is unknown. The atypically spliced exon
removes 37 amino acids from a region of c-Cbl that is very highly
conserved among the known Cbl proteins (19). A nearby
mutation, at residue 316 in C. elegans Sli-1, results in a
severe loss-of-function phenotype (64). Both the C. elegans mutation and the c-Cbl
/
mutation described here occur within a large block of homology that is
within a region of c-Cbl that encodes a novel PTB domain, the boundaries of which have not yet been mapped precisely
(53). This domain is functionally distinct from a conserved,
more C-terminal peptide sequence that is deleted in the oncogenic
70Z-Cbl protein (1). Importantly, we have seen no evidence
that the variant protein produced in c-Cbl
/
mice results in a gain-of-function phenotype. Indeed deletions that
impinge on the region affected in the c-Cbl mutant mice destabilize the
full-length protein and render the v-Cbl protein inactive (reference
53 and unpublished results). Residual protein
expression cannot be excluded whenever a targeting event preserves any
part of the coding region of the gene of interest, as detection of residual expression is limited by the sensitivity of the antisera used.
The large size of the c-Cbl gene (3a) will hamper complete deletion of the locus.
Tissue hyperplasia in c-Cbl mutant mice.
Loss of c-Cbl was
characterized by hyperplastic changes in lymphoid and mammary tissues.
The abundant EMH observed in the spleen appeared to be a direct
consequence of the loss of c-Cbl, as there was no evidence of stimuli,
such as anemia or bone marrow hypoplasia, that could have triggered
this response. In the absence of such an underlying cytopenia in the
bone marrow, and the presence of thrombocythemia with normal numbers of
circulating erythrocytes and granulocytes, the EMH should be regarded
as a pathological rather than a physiological response (47).
The accumulation of the large number of megakaryocytes in the spleens
of c-Cbl mutant mice may arise from dysregulated paracrine or autocrine signalling loops. Interestingly, c-Cbl is a prominent
phosphoprotein in thrombopoietin-stimulated cells (7, 35,
45) and sustained activation of the ERK-mitogen-activated protein
(MAP) kinase pathway promotes autocrine secretion of megakaryocyte
differentiation factors from myeloid cells in vitro (42).
Enhanced growth factor responsiveness may also account for the altered
mammary morphology seen in c-Cbl mutant mice. Members of the EGF ligand
and receptor families are interesting candidates for perturbed
signalling in this tissue, given their prominent role in mammary
branching and development (10, 12, 15, 49, 57), Sli-1's
proposed role in attenuating EGF receptor signalling in C. elegans (64), and c-Cbl's interaction with the EGF
receptor in murine cell lines (4, 17).
Although chromosomal aberrations occur in the region of the
c-Cbl locus in a small number of leukemias, it is unclear
whether loss of c-Cbl is directly involved in transformation
(46). While we did see hyperplastic changes involving
lymphoid and myeloid lineage cells that may represent premalignant
lesions, we did not see the development of frank tumors in the c-Cbl
mutant mice over a period of 8 to 12 months. Loss of c-Cbl does not
appear to have phenocopied the effects of overexpression of v-Cbl in vivo (27). If indeed v-Cbl acts as a dominant negative for
c-Cbl (53), our findings indicate that v-Cbl probably also
blocks the activity of other Cbl proteins in exerting its transforming effects.
T-cell and bone development in c-Cbl-deficient mice.
Thymocytes represent one of the most abundant sites of c-Cbl
expression, and c-Cbl has been strongly implicated in TCR signalling. It was therefore of considerable interest to investigate the
consequences of c-Cbl depletion for T-cell development. Development of
a functional T-cell repertoire occurred normally in
c-Cbl
/
mice as evidenced by a correct ratio
of CD4 and CD8 single- and double-positive cells and normal in vivo
responses to antigen. That T-cell development was not severely affected
in c-Cbl
/
mice is surprising for several
reasons: the surface expression of CD4, CD8, and TCR was increased in
c-Cbl
/
thymocytes; there was
hyperphosphorylation of intracellular proteins in response to receptor
cross-linking; and there was a marked qualitative difference between
wild-type and c-Cbl
/
thymocytes in that the
latter responded acutely to a TCR-mediated signal in the absence of the
normal requirement for coreceptor aggregation (63). Perhaps
c-Cbl occupies an unusual niche as a negative regulator that finely
tunes T-cell development rather than being one of the critical positive
components of T-cell signalling for which a severe loss-of-function
phenotype is normally seen (reviewed in reference
41). Alternatively, redundancy with Cbl-b may allow
cells to accommodate the loss of c-Cbl, as is seen with Lck and Fyn in
mice that are mutant for these genes (18).
Increased expression of the TCR and its coreceptors in c-Cbl mutant
mice is of interest given the proposed role of c-Cbl in mediating
degradation of the CSF-1 receptor (60). The increased expression of CD4 and CD8 in the double-positive thymocytes closely resembles that seen in mice that are deficient in a specific splice variant of CD45 (23). The altered CD4-CD8 expression seen in CD45 mutant mice may be a consequence of the profound block in thymocyte development that occurs at the transition from immature CD4-CD8 double-positive cells to mature, single-positive cells. However, it is notable that c-Cbl
/
mice do
not display a similar block in their development. Whether the cell
surface changes observed in the c-Cbl
/
mice
reflects a direct effect of loss of c-Cbl, such as increased stability
of these proteins, or an altered T-cell developmental sequence requires
further investigation.
c-Cbl phosphorylation is reduced in osteoclast-like cells from c-Src
mutant mice, indicating that c-Cbl may be involved in signalling by Src
(51), which in turn is required for osteoclast activity and
bone remodelling (50). Consistent with this notion, in vitro
bone resorption by osteoclasts was inhibited with antisense oligonucleotides to c-Cbl. Despite these findings we did not
observe any bone defects in c-Cbl mutant mice. Although Cbl-b
expression was not assessed in the antisense experiments, the
oligonucleotides used were directed to sequences that were
nonhomologous between the Cbl-b and c-Cbl genes. In addition, c-Cbl
expression was more profoundly reduced in this study than in the
experiments by Tanaka et al. (51). Thus, a difference in the
degree or scope of attenuation of Cbl protein expression does not
readily explain the discrepancy between the two studies. Rather this
difference more likely reflects the assays used, one in vitro and the
other measuring steady-state bone morphology in vivo. Detailed bone
morphometry and in vitro analysis of c-Cbl
/
osteoclast activity is currently in progress to further characterize the role of c-Cbl in these cells.
c-Cbl as a negative regulator of ZAP-70.
Our analysis of
signalling via the TCR-CD3 complex and the CD4 receptor on thymocytes
has provided compelling evidence that c-Cbl acts as a negative
regulator of the ZAP-70 protein tyrosine kinase. The initial analysis
of CD3-mediated signalling revealed a marked induction in ZAP-70
tyrosine phosphorylation (Fig. 7). Three other proteins in
c-Cbl-deficient thymocytes also revealed a massive induction in
tyrosine phosphorylation following CD3 cross-linking. Based on their
relative mobilities, two of these proteins may represent the ZAP-70
substrates SLP-76 and pp36-38 (or LAT) (44a, 62).
Importantly, costimulation of normal thymocytes with anti-CD3-CD4
antibodies induced a level of phosphorylation of ZAP-70 that was only
slightly lower than that seen in c-Cbl-deficient thymocytes (Fig. 7B).
Despite this, phosphoproteins other than ZAP-70 showed a massive
increase in c-Cbl-deficient thymocytes costimulated with anti-CD3-CD4.
Thus, the activating signal appears to be enhanced by c-Cbl depletion
beyond that accounted for by an activation of ZAP-70 alone.
A striking aspect of the response of c-Cbl
/
thymocytes to receptor cross-linking was that loss of c-Cbl abrogated
the normal requirement for CD4-TCR costimulation for ZAP-70 activation
in thymocytes (63). TCR signalling in these cells was not
completely deregulated, however, as a signal through CD3 was still
necessary for ZAP-70 activation. In normal CD4+
CD8+ thymocytes ZAP-70 forms an inactive complex with the
TCR
chain and cannot be activated by CD3 cross-linking alone because
CD4-Ia interactions sequester available Lck (63). We
considered it possible that loss of c-Cbl increased the availability of
Lck or that Lck was being activated by CD3 alone in
c-Cbl
/
thymocytes. We were also concerned
that a trivial explanation for these findings was that they simply
reflected the increased number of TCR-expressing thymocytes in
c-Cbl
/
mice. This does not appear to be the
case, however, as Lck immune complex kinase assays revealed no obvious
difference in Lck activity between normal and c-Cbl-deficient
thymocytes following CD3 stimulation (Fig. 7B). We would expect that if
the altered signalling observed in c-Cbl
/
thymocytes reflected an expanded TCR-expressing pool, then Lck activation would parallel the other intracellular changes we observed. The profound CD3-mediated intracellular phosphorylation that occurred in c-Cbl
/
thymocytes in the absence Lck
activation indicated that signalling through ZAP-70 had become
uncoupled from Lck activation in these cells. This implied that a
kinase other than Lck may be responsible for inappropriate activation
of ZAP-70 in CD3-cross-linked c-Cbl
/
thymocytes. Several reports have described an interaction between c-Cbl
and the CD3
chain-associated Src family kinase, Fyn (14, 16,
55). Although it is possible that the loss of c-Cbl increases the
availability of Fyn to phosphorylate ZAP-70 following CD3
cross-linking, we have found no evidence of this (data not shown). Alternatively there may be a direct loss of ZAP-70 regulation so that a
normally weak signal via CD3 is sufficient to trigger its activation.
Consistent with the notion that loss of c-Cbl may impact directly on
ZAP-70 regulation is the recent finding that the c-Cbl PTB domain binds
selectively to Tyr-292 of ZAP-70 (32). Phosphorylated
Tyr-292 is thought to negatively regulate ZAP-70 through the binding of
regulatory molecules (24). We aim to further test this
hypothesis by generating thymocyte cell lines from
c-Cbl
/
mice into which wild-type and mutant
alleles of the gene can be introduced.
Experiments first performed in C. elegans, where the weak
signal from a reduction-of-function Let-23 receptor mutant is rescued by the depletion of Sli-1, provided the first indication that Cbl
proteins may negatively regulate tyrosine kinases (64). Our
findings, together with studies revealing the suppressive effect of
c-Cbl overexpression on Syk kinase activity, provides compelling
evidence for c-Cbl to be classified as a negative regulator of the
Syk/ZAP-70 family of tyrosine kinases. Peptides closely matching the
Tyr-292 negative regulatory sequence are represented in several other
proteins to which c-Cbl binds, including the EGF receptor, Syk, and
platelet-derived growth factor alpha (32), suggesting a
potential general mechanism for c-Cbl regulation of protein tyrosine
kinases. While our observations support this general mechanism for
c-Cbl action, the moderate phenotype of the
c-Cbl
/
mice suggests that substantial
functional redundancy may exist with other Cbl family members. Further
elucidation of the mechanism by which this unique family of proteins
regulates intracellular signalling is likely to be of considerable
importance, given the central role that tyrosine kinases play in
controlling cell survival, growth, and differentiation.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from Howard Hughes Medical
Institute and Wellcome Trust and NH&MRC, Australia. D.D.L.B. is a
Howard Hughes International Research Scholar.
We are indebted to Frank Kontgen for assistance in gene targeting and
to Fiona Christensen for excellent assistance with animals and
microinjection. We very much appreciate extensive histological processing performed by Lynn Trute, additional processing by Keith Cole, and assistance with fluorescence-activated cell sorter analyses by Ralph Rossi, Gillian Bradford, Brenda Williams, and Leslie Barber.
We thank David Tarlington, Andreas Strasser, Ken Shortman, Wu Li,
Kirsten Puls, Brian Drucker, Larry Samelson, and Sandy Morse for
reagents and valuable advice and members of the Peter Mac for comments
on the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Research
Division, Peter MacCallum Cancer Institute, Locked Bag 1 A'Beckett
St., Melbourne 3000, VIC, Australia. Phone: 61-3-96561296. Fax:
61-3-96561411. E-mail:
d.bowtell{at}pmci.unimelb.edu.au.
 |
REFERENCES |
| 1.
|
Andoniou, C. E.,
C. Thien, and W. Y. Langdon.
1994.
Tumour induction by activated Abl involves tyrosine phosphorylation of the product of the Cbl oncogene.
EMBO J.
13:4515-4523[Medline].
|
| 2.
|
Blake, T. J.,
M. Shapiro,
H. D. Morse, and W. Y. Langdon.
1991.
The sequences of the human and mouse c-Cbl proto-oncogenes show v-Cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif.
Oncogene
6:653-657[Medline].
|
| 3.
|
Bonita, D. P.,
S. Miyake,
M. R. Lupher,
W. Y. Langdon, and H. Band.
1997.
Phosphotyrosine binding domain-dependent upregulation of PDGF receptor signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity.
Mol. Cell. Biol.
17:4597-4610[Abstract].
|
| 3a.
| Bowtell, D. Unpublished data.
|
| 4.
|
Bowtell, D., and W. Y. Langdon.
1995.
The protein product of the c-cbl oncogene rapidly complexes with the EGF receptor and is tyrosine phosphorylated following EGF stimulation.
Oncogene
11:1561-1567[Medline].
|
| 5.
|
Bradley, T. R.,
G. S. Hodgson, and M. Rosendaal.
1978.
The effect of oxygen tension on haemopoietic and fibroblast cell proliferation in vitro.
J. Cell. Physiol.
97:517-522[Medline].
|
| 6.
|
Bradley, T. R.,
E. R. Stanley, and M. A. Sumner.
1971.
Factors from mouse tissues stimulating colony growth of mouse bone marrow cells in vitro.
Aust. J. Exp. Biol. Med. Sci.
49:595-603[Medline].
|
| 7.
|
Brizzi, M. F.,
P. Dentelli,
L. Lanfrancone,
A. Rosso,
P. G. Pelicci, and L. Pegoraro.
1996.
Discrete protein interactions with the Grb2/c-Cbl complex in Scf- and Tpo-mediated myeloid cell proliferation.
Oncogene
13:2067-2076[Medline].
|
| 8.
|
Chan, A. C.,
M. Dalton,
R. Johnson,
G. H. Kong,
T. Wang,
R. Thoma, and T. Kurosaki.
1995.
Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is required for lymphocyte antigen receptor function.
EMBO J.
14:2499-2508[Medline].
|
| 9.
|
Coffman, R. L.
1982.
Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development.
Immunol. Rev.
69:5-23[Medline].
|
| 10.
|
Coleman, S.,
G. B. Silberstein, and C. W. Daniel.
1988.
Ductal morphogenesis in the mouse mammary gland: evidence supporting a role for epidermal growth factor.
Dev. Biol.
127:304-315[Medline].
|
| 11.
|
Cory, G.,
R. C. Lovering,
S. Hinshelwood,
L. MacCarthy-Morrogh,
R. J. Levinsky, and C. Kinnon.
1995.
The protein product of the c-Cbl protooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of brutons tyrosine kinase.
J. Exp. Med.
182:611-615[Abstract/Free Full Text].
|
| 12.
|
Curtis, S. W.,
T. Washburn,
C. Sewall,
R. Diaugustine,
J. Lindzey,
J. F. Couse, and K. S. Korach.
1996.
Physiological coupling of growth factor and steroid receptor signaling pathways estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor.
Proc. Natl. Acad. Sci. USA
93:12626-12630[Abstract/Free Full Text].
|
| 13.
|
Donovan, J. A.,
R. L. Wange,
W. Y. Langdon, and L. E. Samelson.
1994.
The protein product of the c-cbl protooncogene is the 120-kDa tyrosine-phosphorylated protein in Jurkat cells activated via the T cell antigen receptor.
J. Biol. Chem.
269:22921-22924[Abstract/Free Full Text].
|
| 14.
|
Fournel, M.,
D. Davidson,
R. Weil, and A. Veillette.
1996.
Association of tyrosine protein kinase zap-70 with the protooncogene product p120(c-cbl) in T lymphocytes.
J. Exp. Med.
183:301-306[Abstract/Free Full Text].
|
| 15.
|
Fowler, K. J., et al.
1995.
A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation.
Proc. Natl. Acad. Sci. USA
92:1465-1469[Abstract/Free Full Text].
|
| 16.
|
Fukazawa, T.,
K. A. Reedquist,
T. Trub,
S. Soltoff,
G. Panchamoorthy,
B. Druker,
L. Cantley,
S. E. Shoelson, and H. Band.
1995.
The SH3 domain-binding T cell tyrosyl phosphoprotein p120 demonstration of its identity with the c-cbl protooncogene product and in vivo complexes with Fyn, Grb2, and phosphatidylinositol 3-kinase.
J. Biol. Chem.
270:19141-19150[Abstract/Free Full Text].
|
| 17.
|
Galisteo, M. L.,
I. Dikic,
A. G. Batzer,
W. Y. Langdon, and J. Schlessinger.
1995.
Tyrosine phosphorylation of the c-Cbl proto-oncogene protein product and association with epidermal growth factor (EGF) receptor upon EGF stimulation.
J. Biol. Chem.
270:20242-20245[Abstract/Free Full Text].
|
| 18.
|
Groves, T.,
P. Smiley,
M. P. Cooke,
K. Forbush,
R. M. Perlmutter, and C. J. Guidos.
1996.
Fyn can partially substitute for Lck in T lymphocyte development.
Immunity
5:417-428[Medline].
|
| 19.
|
Hime, G. R.,
M. P. Dhungat,
A. Ng, and D. Bowtell.
1997.
D-cbl, the Drosophila homologue of the c-cbl proto-oncogene, interacts with the Drosophila EGF receptor in vivo, despite lacking c-terminal adaptor binding sites.
Oncogene
14:2709-2719[Medline].
|
| 20.
|
Jongeward, G. D.,
T. R. Clandinin, and P. W. Sternberg.
1995.
Sli-1, a negative regulator of let-23-mediated signaling in C. elegans.
Genetics
139:1553-1566[Abstract].
|
| 21.
|
Keane, M. M.,
O. M. Riverolezcano,
J. A. Mitchell,
K. C. Robbins, and S. Lipkowitz.
1995.
Cloning and characterization of Cbl-b a SH3 binding protein with homology to the c-Cbl proto-oncogene.
Oncogene
10:2367-2377[Medline].
|
| 22.
|
Kim, T. J.,
Y. T. Kim, and S. Pillai.
1995.
Association of activated phosphatidylinositol 3-kinase with p120(cbl) in antigen receptor-ligated B cells.
J. Biol. Chem.
270:27504-27509[Abstract/Free Full Text].
|
| 23.
|
Kishihara, K., et al.
1993.
Normal B-lymphocyte development but impaired T-cell maturation in cd45-exon6 protein tyrosine phosphatase deficient mice.
Cell
74:143-156[Medline].
|
| 24.
|
Kong, G. H.,
M. Dalton,
J. B. Wardenburg,
D. Straus,
T. Kurosaki, and A. C. Chan.
1996.
Distinct tyrosine phosphorylation sites in Zap-70 mediate activation and negative regulation of antigen receptor function.
Mol. Cell. Biol.
16:5026-5035[Abstract].
|
| 25.
|
Kontani, K.,
I. Kukimoto,
H. Nishina,
S. Hoshino,
O. Hazeki,
Y. Kanaho, and T. Katada.
1996.
Tyrosine phosphorylation of the c-cbl proto-oncogene product mediated by cell surface antigen cd38 in hl-60 cells.
J. Biol. Chem.
271:1534-1537[Abstract/Free Full Text].
|
| 26.
|
Kontgen, F.,
R. J. Grumont,
A. Strasser,
D. Metcalf,
R. L. Li,
D. Tarlinton, and S. Gerondakis.
1995.
Mice lacking the c-Rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression.
Genes Dev.
9:1965-1977[Abstract/Free Full Text].
|
| 27.
|
Langdon, W. Y.,
J. W. Hartley,
S. P. Klinken,
S. K. Ruscetti, and H. C. Morse.
1989.
v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas.
Proc. Natl. Acad. Sci. USA
86:1168-1172[Abstract/Free Full Text].
|
| 28.
|
Langdon, W. Y.,
C. D. Hyland,
R. J. Grumont, and H. D. Morse.
1989.
The c-cbl proto-oncogene is preferentially expressed in thymus and testis tissue and encodes a nuclear protein.
J. Virol.
63:5420-5424[Abstract/Free Full Text].
|
| 29.
|
Liu, Y. C.,
C. Elly,
W. Y. Langdon, and A. Altman.
1997.
Ras-dependent Ca2+-stimulated activation of nuclear factor of activated T cells by a constitutively active Cbl mutant in T cells.
J. Biol. Chem.
272:168-173[Abstract/Free Full Text].
|
| 30.
|
Liu, Y. C.,
Y. H. Liu,
C. Elly,
H. Yoshida,
S. Lipkowitz, and A. Altman.
1997.
Serine phosphorylation of cbl induced by phorbol ester enhances its association with 14-3-3 proteins in T cells via |